Publications scientifiques sur le VIH

Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection [abstract].
2020
Value in Health.
La EM, Talbird SE, Brogan AJ, Davis AE.
23:S174. Proceedings of the Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2020.
Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection.
2020
La EM, Talbird SE, Brogan AJ, Davis AE.
Poster #PIN31 presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 18-20 2020; virtual.
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates [abstract].
2020
Le Hingrat Q, Collin G, Charpentier C, et al.
PEB0122. Presented at: 23rd Annual International AIDS Conference; July 6-10 2020; virtual.
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
2020
Le Hingrat Q, Collin G, Charpentier C, et al.
Poster #PEB0122 presented at: 23rd Annual International AIDS Conference; July 6-10 2020; virtual.
Comparable efficacy of ibalizumab in combination with 1 or 2 fully active agents [abstract].
2020
Top Antivir Med.
DeJesus E, McGary C, Mesquita P, et al.
"28 (1):181. Proceedings of the 2020 Conference on Retroviruses and Opportunistic Infections. "